Lurbinectedin is a chemotherapy drug that is used to treat small cell lung cancer (SCLC) in patients who have received previous treatments but did not respond well to them. According to the sources provided, there are some potential long-term side effects associated with taking lurbinectedin.

The first source [1] states that there are no known patent challenges for lurbinectedin, which suggests that the drug is still under patent protection and has not yet become widely available as a generic medication. This may impact the accessibility and affordability of the drug for some patients.

The second source [2] provides information on the potential side effects of lurbinectedin. Some of the more common side effects include fatigue, nausea, vomiting, and loss of appetite. However, there are also some more serious side effects that may occur, such as low white blood cell count, anemia, and increased risk of infection. These side effects may persist for a longer period of time and may require ongoing medical treatment.

The third source [3] also lists some potential side effects of lurbinectedin, including fatigue, nausea, and decreased appetite. In addition, the source notes that the drug may cause some changes in the way the heart functions, such as an irregular heartbeat or a decrease in the amount of blood that the heart pumps. These effects may be more long-lasting and may require ongoing monitoring by a healthcare provider.

Overall, while lurbinectedin may be an effective treatment option for some patients with SCLC, it is important to be aware of the potential side effects, both short-term and long-term. Patients should discuss any concerns or questions they have about the drug with their healthcare provider.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.mayoclinic.org/drugs-supplements/lurbinectedin-intravenous-route/side-effects/drg-20490804?p=1
[3] https://www.zepzelca.com/zepzelca-side-effects/